NS Pharma, Inc.
Koichi Iizuka is an experienced professional in the pharmaceutical industry, currently serving as Executive in Residence at NS Pharma, Inc. since April 2025. Previously, from October 2003 to March 2020, Koichi held multiple leadership positions at Takeda Pharmaceutical Company Ltd, including Head of Pipeline Strategy, where responsibilities included portfolio strategy and Japan growth strategy, and Japan Customer Insight, Planning, and Development, facilitating strategic dialogue and M&A assessments. Koichi also contributed as Japan CNS Business Lead, focusing on growth strategy and partner management in the CNS therapeutic area. Earlier experience includes a role in finance planning and operations at TAP Pharmaceuticals. Academically, Koichi holds a Master of Science in Management with a focus on technology strategy from MIT Sloan School of Management.
This person is not in any teams
This person is not in any offices
NS Pharma, Inc.
2 followers
NS Pharma, Inc. (NSP) located in Paramus New Jersey is a subsidiary of Nippon Shinyaku Co., Ltd. Founded in 1999 in the United States, NSP is engaged in clinical studies and partnering with global pharmaceutical companies, venture companies and research institutes. NSP serves as a contact point for connecting Japan/Asia and the world, developing drug candidates invented in Japan and out-license them to the world. From the world to Japan/Asia, NSP in-license promising drug candidates to the Japanese/Asian Markets. In coordination with parent company, Nippon Shinyaku, Co., Ltd., NSP will first and foremost develop and supply safe and highly effective pharmaceuticals through clinical studies. NSP aims to be an indispensable entity in the healthcare industry in line with the guidelines for action “Challenge”, “Speed”, and “Investigation”.